FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000008/US/NP	10/565,713	
APPLICANT		
Scheller, D. et al.		
FILING DATE	GROUP	
25 January 2006	1627	

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		2005/0037983	02-17-2005	Dinan	A61K 31/7048	03-11-2004
		2005/0038015	02-17-2005	Bronzova, et al.	A61K 31/551	02-11-2003
		4,769,028	09-06-1988	Hoffmann, et al.	A61K 9/70	07-17-1986

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No

OTHER	OTHER DOCUMENTS				
Ref. Desig.	Examiner's Initials				
		Beaulieu, et al., "N,N-disubstituted 2-aminotetralins are potent D-2 dopamine receptor agonists" European Journal of Pharm., Oct 1984, vol. 105, pp. 15-21 (Abstract)			
		Belluzzi, et al., "N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's" Mov. Dis., Mar 1994, 9:2, pp 937-946 (Abstract)			
		Bertaine-Anglade, V., et al. (2006) "Antidepressant properties of Rotigotine in experimental models of depression," European Journal of Pharmacology. 548: 106-114			
		Corrigan, et al., "Comparison of Pramipexole, Fluoxetine, and Placebo in Patients with Major Depression" Depression and Anxiety, 2000, Vol. 11, 58-65 (Abstract)			
		Goetz, G., et al. (2003) "The Unified Parkinson's Disease Rating Scale (UPDRS): Status and Recommendations," Movement Disorders. 18 (7): 738-750			
		Muscat, et al., "Antiepressant-like effects of dopamine agonists in an animal model of depression" Bio Psychiatry, May 1992, Vol. 31, Issue 9, pp 937-946 (Abstract)			
		Rotigotine (Transdermal Route) (2007) http://www.mayoclinic.com/health/drug- information/DR602471/DSECTION=proper-use. Pg 1-8			
		Scheller, D., et al. (2009) "The in vitro receptor profile of Rotigotine: a new agent for the treatment of Parkinson's disease," Naunyn-Schmiedeberg's Arch. Pharmacol. 379: 73-86			
		Wang, W., et al. (2007) "Effects of Apomorphine on the Expression of Learned Helplessness Behavior," Chinese Journal of Physiology. 50 (2): 63-68			

Examiner:	Date Considered:

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET No.	SERIAL NO.	
6102-000008/US/NP	10/565,713	
Applicant		
Scheller, D. et al.		
FILING DATE	GROUP	
25 January 2006	1627	

OTHE	OTHER DOCUMENTS			
Ref. Desig.	Examiner's Initials			
		http://en.wikipedia.org/wiki/Apomorphine (printed 6 June 2011)		
		Office Action, dated November 1, 2002 issued in U.S. Application No.09/647,290		
		Office Action, dated September 13, 2007 issued in U.S. Application No.10/936,620		
		Office Action, dated May 1, 2008 issued in U.S. Application No.10/936,620		
		Office Action, dated October 16, 2008 issued in U.S. Application No.10/587,637		
		Office Action, dated January 26, 2009 issued in U.S. Application No.10/936,620		
		Office Action, dated September 2, 2009 issued in U.S. Application No.10/587,637		
		Office Action, dated October 23, 2009 issued in U.S. Application No.10/565,699		
		Office Action, dated November 6, 2009 issued in U.S. Application No.10/936,620		
		Office Action, dated May 27, 2010 issued in U.S. Application No.10/565,699		
		Office Action, dated June 7, 2010 issued in U.S. Application No.10/587,637		
		Office Action, dated October 8, 2010 issued in U.S. Application No.10/936,620		
		Office Action, dated February 14, 2011 issued in U.S. Application No.10/565,699		

Examiner:	Date Considered: